Boteng Co., Ltd. expects a net profit of 96.3399 million yuan in 2025, a year-on-year increase of 133.48%.

NightAirdropper · 2026-04-05T10:20:55+00:00

Boteng Co., Ltd. achieved operating revenue of 3.42 billion yuan in 2025, a year-on-year increase of 13.54%; net profit attributable to the company amounted to 96.3399 million yuan, a year-on-year increase of 133.48%. The growth mainly came from small-molecule API and emerging businesses, but the small-molecule formulations business declined slightly by 4% due to a downturn in market demand.

NightAirdropper

2026-04-05 10:20:55

Abstract generation in progress

Beijing Business Daily reported (Reporter Ding Ning). On the evening of April 3, Boteng Co., Ltd. (300363) released its 2025 annual report, which shows that in 2025 the company achieved operating revenue of RMB 3.42 billion, up 13.54%; net profit attributable to shareholders was RMB 96.3399 million, up 133.48%.

Boteng Co., Ltd. said that, looking at business segments, during the reporting period, the growth in the company’s operating revenue came from its small-molecule API business and two major new business segments—cell and gene therapy and new molecules. Specifically, revenue from the small-molecule API business increased by about 13% year over year; revenue from the cell and gene therapy business increased by about 36% year over year; and revenue from the new molecules business increased by about 224% year over year. Revenue from the company’s small-molecule formulations segment decreased by about 4% year over year, mainly because domestic generic drug formulations demand was affected by a downturn in market demand brought about by the centralized procurement policy.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.